Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

456
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
456
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

363
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
363
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of platelet transfusion on outcomes in trauma patients.

Critical care (London, England)·2022
Same author

Coagulation standards in healthy newborns and infants.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2020
Same author

[How to manage anticoagulant treatment in case of invasive procedures (surgery, endoscopy…)].

Revue des maladies respiratoires·2019
Same author

[Recommendations for best practice in the management of venous thromboembolic disease in adults. Long version].

Revue des maladies respiratoires·2019
Same author

[Recommendations of good practice for the management of thromboembolic venous disease in adults. Short version].

Revue des maladies respiratoires·2019
Same author

User-friendly recommendations on antiplatelet agents: At last, a readable document.

Revista espanola de anestesiologia y reanimacion·2018
Same journal

Renal function and venous thromboembolic diseases.

Journal des maladies vasculaires·2016
Same journal

[Ankle-brachial index screening for peripheral artery disease in high cardiovascular risk patients. Prospective observational study of 370 asymptomatic patients at high cardiovascular risk].

Journal des maladies vasculaires·2016
Same journal

[Erratum to "When to worry about before a vascular chronic leg ulcer?" [J. Mal. Vasc. 41 (2016) 307-314]].

Journal des maladies vasculaires·2016
Same journal

[Deep venous thrombosis of the upper limb in a violin player: The "bow syndrome"].

Journal des maladies vasculaires·2016
Same journal

[Economic consequences of biological monitoring and medical complications of injectable anticoagulants in France].

Journal des maladies vasculaires·2016
Same journal

[Vitamin K antagonist, direct oral anticoagulants: Where is the truth?]

Journal des maladies vasculaires·2016
See all related articles

Related Experiment Video

Updated: Mar 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

[Direct oral anticoagulant associated bleeding].

A Godier1, A-C Martin2, N Rosencher3

  • 1Service d'anesthésie réanimation, fondation ophtalmologique Adolphe-de-Rothschild, 75019 Paris, France; Inserm UMRS 1140, faculté de pharmacie, université Paris Descartes, Paris, France.

Journal Des Maladies Vasculaires
|June 15, 2016
PubMed
Summary
This summary is machine-generated.

Direct oral anticoagulants (DOACs) can cause bleeding. While specific antidotes like idarucizumab are available, managing DOAC-induced bleeding requires careful consideration of reversal agents and plasma concentration monitoring.

Keywords:
AVKAnticoagulant oral directAnticoagulantsAntidoteBleedingDirect oral anticoagulantHémorragieHémostatiquesReversal

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.2K

Area of Science:

  • Pharmacology and Toxicology
  • Cardiology
  • Hematology

Background:

  • Direct oral anticoagulants (DOACs) are widely used for stroke prevention in atrial fibrillation and venous thromboembolism treatment.
  • Hemorrhagic complications are a significant concern with DOAC therapy.
  • Effective management strategies for DOAC-induced bleeding are crucial.

Purpose of the Study:

  • To provide an updated overview of managing bleeding complications associated with direct oral anticoagulants.
  • To integrate the role of newly available and developing antidotes in DOAC reversal.
  • To emphasize the importance of measuring DOAC plasma concentrations for guiding treatment decisions.

Main Methods:

  • Review of current literature on DOAC-induced bleeding management.
  • Analysis of available and investigational reversal agents, including specific antidotes and supportive measures.
  • Discussion on the utility of pharmacokinetic monitoring (plasma concentration measurement).

Main Results:

  • Idarucizumab is an approved antidote for dabigatran.
  • Andexanet alfa (for anti-Xa agents) and aripazine (for all DOACs) are under development.
  • Prothrombin concentrates have uncertain efficacy for DOAC reversal.
  • Hemodialysis and oral charcoal are options for specific scenarios.
  • DOAC plasma concentration measurement is essential for effective reversal.

Conclusions:

  • Management of DOAC-induced bleeding is evolving with the advent of specific antidotes.
  • The availability of idarucizumab and the development of other antidotes offer improved therapeutic options.
  • Accurate DOAC plasma concentration monitoring is critical for guiding appropriate reversal strategies and improving patient outcomes.